The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Neoadjuvant therapy and organ preservation in rectal cancer
Manisha Palta, MD, Duke University, Durham, NC, discusses the latest advances in rectal cancer, including the advent of total neoadjuvant therapy. Dr Palta additionally highlights the role of organ preservation in rectal cancer, especially with the findings from the Phase II OPRA (NCT02008656) and the Phase III OPERA trial (NCT02505750). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
